DE60042600D1 - Er in der behandlung chronisch entzündlicher krankheiten wirksam ist - Google Patents

Er in der behandlung chronisch entzündlicher krankheiten wirksam ist

Info

Publication number
DE60042600D1
DE60042600D1 DE60042600T DE60042600T DE60042600D1 DE 60042600 D1 DE60042600 D1 DE 60042600D1 DE 60042600 T DE60042600 T DE 60042600T DE 60042600 T DE60042600 T DE 60042600T DE 60042600 D1 DE60042600 D1 DE 60042600D1
Authority
DE
Germany
Prior art keywords
sub
cells
compound
treatment
ability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042600T
Other languages
English (en)
Inventor
Fionula Mary Brennan
Marc Mathilda And Feldmann
Brian M J Foxwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Mathilda and Terence Kennedy Institute of Rheumatology Trust
Kennedy Institute of Rheumotology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mathilda and Terence Kennedy Institute of Rheumatology Trust, Kennedy Institute of Rheumotology filed Critical Mathilda and Terence Kennedy Institute of Rheumatology Trust
Application granted granted Critical
Publication of DE60042600D1 publication Critical patent/DE60042600D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
DE60042600T 1999-09-24 2000-09-25 Er in der behandlung chronisch entzündlicher krankheiten wirksam ist Expired - Lifetime DE60042600D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922505.4A GB9922505D0 (en) 1999-09-24 1999-09-24 Therapeutic methods and compounds
PCT/GB2000/003660 WO2001021202A2 (en) 1999-09-24 2000-09-25 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells

Publications (1)

Publication Number Publication Date
DE60042600D1 true DE60042600D1 (de) 2009-09-03

Family

ID=10861451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042600T Expired - Lifetime DE60042600D1 (de) 1999-09-24 2000-09-25 Er in der behandlung chronisch entzündlicher krankheiten wirksam ist

Country Status (10)

Country Link
US (1) US7390630B1 (de)
EP (1) EP1220922B1 (de)
JP (1) JP2003509471A (de)
AT (1) ATE437218T1 (de)
AU (1) AU7436100A (de)
CA (1) CA2383462A1 (de)
DE (1) DE60042600D1 (de)
ES (1) ES2330077T3 (de)
GB (1) GB9922505D0 (de)
WO (1) WO2001021202A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240011A1 (en) * 2002-08-14 2006-10-26 Delphine Boulanger Use of nf-kappa b inhibitors for the treatment of mastitis
JP4534046B2 (ja) * 2004-04-14 2010-09-01 有限会社金沢大学ティ・エル・オー 臓器特異的幹細胞の増殖方法及び増殖装置
WO2019060330A1 (en) * 2017-09-19 2019-03-28 Momenta Pharmaceuticals, Inc. METHODS OF PREDICTION OF RESPONSE TO TREATMENT

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5085985A (en) * 1987-11-12 1992-02-04 Becton Dickinson & Co. Monoclonal antibodies and their use in a method for monitoring subsets of activated T cells
WO1997033977A1 (fr) * 1996-03-13 1997-09-18 Shionogi & Co., Ltd. Clone de cellules t humaines specifique a la polyarthrite rhumatoide

Also Published As

Publication number Publication date
JP2003509471A (ja) 2003-03-11
US7390630B1 (en) 2008-06-24
WO2001021202A2 (en) 2001-03-29
CA2383462A1 (en) 2001-03-29
ATE437218T1 (de) 2009-08-15
ES2330077T3 (es) 2009-12-04
WO2001021202A3 (en) 2001-10-11
GB9922505D0 (en) 1999-11-24
EP1220922A2 (de) 2002-07-10
EP1220922B1 (de) 2009-07-22
AU7436100A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
Kimber et al. A murine local lymph node assay for the identification of contact allergens: assay development and results of an initial validation study
Hao et al. conversion of T follicular helper cells to T follicular regulatory cells by interleukin‐2 through transcriptional regulation in systemic lupus Erythematosus
Lacetera et al. Effects of nonesterified fatty acids on lymphocyte function in dairy heifers
Lexmond et al. FOXP3+ Tregs require WASP to restrain Th2-mediated food allergy
Petrova et al. p38 MAPK signalling regulates cytokine production in IL-33 stimulated Type 2 Innate Lymphoid cells
Day et al. Regulation of epithelial syndecan-1 expression by inflammatory cytokines
Wu et al. Upregulation of inflammatory cytokines and oncogenic signal pathways preceding tumor formation in a murine model of T-cell lymphoma in skin
Charrier et al. Regulation of pancreatic inflammation by connective tissue growth factor (CTGF/CCN 2)
Vucevic et al. Inverse production of IL-6 and IL-10 by abdominal aortic aneurysm explant tissues in culture
DE60042600D1 (de) Er in der behandlung chronisch entzündlicher krankheiten wirksam ist
Huffnagle Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection
Laurent et al. Interleukin‐1β–Activated Microvascular Endothelial Cells Promote DC‐SIGN–Positive Alternatively Activated Macrophages as a Mechanism of Skin Fibrosis in Systemic Sclerosis
EP1747025A4 (de) Verfahren zur diagnose von infektionskrankheiten
Joshi et al. TLR3 modulates immunopathology during a Schistosoma mansoni egg‐driven Th2 response in the lung
Connor et al. Methylenedioxymethamphetamine-induced suppression of interleukin-1β and tumour necrosis factor-α is not mediated by serotonin
Shi et al. Elevated IL‐23 in skin promotes IL‐23 derived Th17 responses in leprosy patients
Fukuyama et al. Detection of low-level environmental chemical allergy by a long-term sensitization method
Lion et al. Quantification of IFN-γ produced by human purified NK cells following tumor cell stimulation: Comparison of three IFN-γ assays
Maher et al. Repair of DNA Damage Induced in Human Fibroblasts by N-Substituted Aryl Compounds ¹. 2
Pindjaková et al. Corneal rat‐to‐mouse xenotransplantation and the effects of anti‐CD4 or anti‐CD8 treatment on cytokine and nitric oxide production
Schieck et al. Can removal areas be used to assess dispersal of red-backed voles?
Di Nuzzo et al. UVB Irradiation of Normal Human Skin Favors the Development of Type‐2 T‐cells In Vivo and in Primary Dermal Cell Cultures¶
Luckschander et al. Phenotyping, functional characterization, and developmental changes in canine intestinal intraepithelial lymphocytes
CA2523297A1 (en) Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte, and utilization of same
Diaz-Romero et al. Coexpression of CD4 and CD8α on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition